TREM-1: A new regulator of innate immunity in sepsis syndrome
Carl Nathan
& Aihao Ding
Department of Microbiology & Immunology, Weill Medical College Cornell University cnathan@med.cornell.edu
Although we have drugs and biologics designed to interfere with the innate immune response, none has been shown to shut down the massive inflammatory reaction that occurs during sepsis. A new pro-inflammatory myeloid-cell receptor might make a better target.
